

Resource Summary Report

Generated by [dkNET](#) on Sep 15, 2026

WSU-DLCL2

RRID:CVCL_1902

Type: Cell Line

Proper Citation

RRID:CVCL_1902

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1902

Proper Citation: RRID:CVCL_1902

Description: Cell line WSU-DLCL2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: [PMID:9607591](#), [PMID:19358282](#), [PMID:22460905](#), [PMID:23699601](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:26727417](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31395879](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: WSU-DLCL2

Synonyms: WSU-DLCL-2, WSU-DLCL(2), WSUDLCL2

Cross References: CLO:CLO_0037068, EFO:EFO_0006775, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03473225, BioSample:SAMN10989570, cancercellines:CVCL_1902, Cell_Model_Passport:SIDM00413, Cosmic:1329090, Cosmic:1629937, Cosmic:1714159,

Cosmic-CLP:1331050, DepMap:ACH-000534, DSMZ:ACC-575, DSMZCellDive:ACC-575, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:1331050, GEO:GSM274708, GEO:GSM887741, GEO:GSM888836, GEO:GSM1035308, GEO:GSM1670582, IARC_TP53:28232, LiGeA:CCLE_593, LINCS_LDP:LCL-1954, PharmacDB:WSUDLCL2_1675_2019, PRIDE:PXD030304, Progenetix:CVCL_1902, Wikidata:Q54994467

ID: CVCL_1902

Record Creation Time: 20220427T221724+0000

Record Last Update: 20260913T010420+0000

Ratings and Alerts

No rating or validation information has been found for WSU-DLCL2.

Warning: Discontinued: ATCC; CRL-11585

Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Wu J, et al. (2026) Hi-C for genome-wide detection of enhancer-hijacking rearrangements in routine lymphoid cancer biopsies. Cell genomics, 6(5), 101166.

Weber PAA, et al. (2026) Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control. Cancer research communications, 6(7), 1619.

Wang B, et al. (2026) Axes of biological variation in diffuse large B cell lymphoma. Cancer cell.

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

L????nd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

Probst P, et al. (2025) Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC. *Molecular cancer therapeutics*, 24(6), 803.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. *Cancer discovery*, 13(8), 1862.

Preston SEJ, et al. (2022) Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype. *Molecular cancer therapeutics*, 21(4), 511.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, 54(1), 116.

Park S, et al. (2020) Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in EZH2 Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma. *Cancers*, 12(9).

Li D, et al. (2019) Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin. *British journal of pharmacology*, 176(19), 3805.

Meyer SN, et al. (2019) Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma. *Immunity*, 51(3), 535.

Yamagishi M, et al. (2019) Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. *Cell reports*, 29(8), 2321.